INOVIQ Ltd
ASX:IIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
INOVIQ Ltd
Revenue
INOVIQ Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
INOVIQ Ltd
ASX:IIQ
|
Revenue
AU$959.3k
|
CAGR 3-Years
41%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Revenue
AU$10.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Revenue
AU$768.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Revenue
AU$741.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Apiam Animal Health Ltd
ASX:AHX
|
Revenue
AU$206.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Revenue
AU$1.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
INOVIQ Ltd
Glance View
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is focused on developing and commercializing a portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Company’s products include hTERT ICC test, which is an immunocytochemistry (ICC) assay that detects hTERT and is used as an adjunct to urine cytology, and EXO-NET RUO, which is a pan-exosome capture tool for isolation of exosomes from body fluids including plasma, urine, and saliva. The company is also developing solutions using SubB2M, NETs, BARD1 and hTERT technologies to improve patient health outcomes.
See Also
What is INOVIQ Ltd's Revenue?
Revenue
959.3k
AUD
Based on the financial report for Jun 30, 2025, INOVIQ Ltd's Revenue amounts to 959.3k AUD.
What is INOVIQ Ltd's Revenue growth rate?
Revenue CAGR 5Y
58%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for INOVIQ Ltd have been 41% over the past three years , 58% over the past five years .
